Skip to main content

Table 2 Patients and Samples analyzed in this study, and result of each assay in each period

From: Comparison of six antibody assays and two combination assays for COVID-19

Days from symptom onset

Total patients, no

Seropositive patients*, no. (%)

Total collected samples, no

Samples with positive result**, no. (%)

Elecsys, no. (%)

SuperFlex_Ab, no. (%)

SuperFlex_IgM, no. (%)

SuperFlex_IgG, no. (%)

SuperFlex_any†, no. (%)

iFlash_IgM, no. (%)

iFlash_IgG, no. (%)

iFlash_any#, no. (%)

Day 1–7

23

14 (60.9%)

53

24 (45.3%)

16 (30.2%)

18 (34.0%)

3 (5.7%)

11 (20.8%)

18 (34.0%)

8 (15.1%)

19 (35.8%)

19 (35.8%)

Day 8–14

39

32 (82.1%)

109

82 (75.2%)

66 (60.6%)

69 (63.3%)

18 (16.5%)

61 (56.0%)

71 (65.1%)

34 (31.2%)

71 (65.1%)

71 (65.1%)

Day 1–14 total

62

46 (74.2%)

162

106 (65.4%)

82 (50.6%)

87 (53.7%)

21 (13.0%)

72 (44.4%)

89 (54.9%)

42 (25.9%)

90 (55.6%)

90 (55.6%)

Day 15–21

29

29 (100%)

78

77 (98.7%)

76 (97.4%)

76 (97.4%)

47 (60.3%)

76 (97.4%)

76 (97.4%)

50 (64.1%)

77 (98.7%)

77 (98.7%)

Day 22–28

19

19 (100%)

45

45 (100%)

45 (100%)

45 (100%)

33 (73.3%)

45 (100%)

45 (100%)

37 (82.2%)

45 (100%)

45 (100%)

Day 29–56

15

15 (100%)

80

80 (100%)

74 (92.5%)

80 (100%)

35 (43.8%)

80 (100%)

80 (100%)

25 (31.3%)

80 (100%)

80 (100%)

Day 57–84

6

6 (100%)

20

20 (100%)

20 (100%)

20 (100%)

3 (15.0%)

20 (100%)

20 (100%)

1 (5.0%)

20 (100%)

20 (100%)

Day 85–112

1

1 (100%)

12

12 (100%)

12 (100%)

12 (100%)

0 (0%)

12 (100%)

12 (100%)

0 (0%)

12 (100%)

12 (100%)

Day 113–140

2

2 (100%)

14

14 (100%)

14 (100%)

14 (100%)

0 (0%)

14 (100%)

14 (100%)

0 (0%)

14 (100%)

14 (100%)

Day 141–182

2

2 (100%)

27

27 (100%)

25 (92.6%)

27 (100%)

0 (0%)

27 (100%)

27 (100%)

0 (0%)

22 (81.5%)

22 (81.5%)

Day 15–182 total

74

74 (100%)

276

275 (99.6%)

266 (96.4%)

274 (99.3%)

118 (42.8%)

274 (99.3%)

274 (99.3%)

113 (40.9%)

270 (97.8%)

270 (97.8%)

Total

136

120 (88.2%)

438

381 (87.0%)

348 (79.5%)

361 (82.4%)

139 (31.7%)

346 (79.0%)

363 (82.9%)

155 (35.4%)

360 (82.2%)

360 (82.2%)

  1. *Patients who were positive for at least one of SARS-CoV-2 specific antibody testing
  2. **Samples with positive result for at least one of SARS-CoV-2 specific antibody testing
  3. The SuperFlex_any is the assay combined with SuperFlex_Ab, SuperFlex_IgM, and SuperFlex_IgG
  4. #The iFlash_any is the assay combined with iFlash_IgM and iFlash_IgG